文献速递脑血管病外科神经重症

甲状腺激素替代治疗对动脉瘤性蛛网膜下腔出血病程与功能结局的影响

Impact of thyroid hormone replacement therapy on the course and functional outcome of aneurysmal subarachnoid hemorrhage.
PubMed 文献 · Acta Neurochir (Wien) · 2024-06-03

该研究纳入2003年1月至2016年6月治疗的995例动脉瘤性蛛网膜下腔出血患者,其中109例(11%)在出血前接受甲状腺激素替代治疗。多因素分析显示,甲状腺激素替代治疗与较低的脑梗死风险(aOR=0.64,95%CI=0.41-0.99,p=0.045)和较差功能结局风险(aOR=0.50,95%CI=0.28-0.89,p=0.018)独立相关,但与院内死亡率无关(aOR=0.69,95%CI=0.38-1.26,p=0.227)。作者认为需进一步实验和临床研究证实结果并阐明机制。

要点

  • 995例动脉瘤性蛛网膜下腔出血患者中109例(11%)出血前接受甲状腺激素替代治疗。
  • 甲状腺激素替代治疗与较低脑梗死风险独立相关(aOR=0.64,95%CI=0.41-0.99,p=0.045)。
  • 甲状腺激素替代治疗与较低不良功能结局风险独立相关(aOR=0.50,95%CI=0.28-0.89,p=0.018)。

核心结论

  • 接受甲状腺激素替代治疗的蛛网膜下腔出血患者缺血相关脑血管事件负担较低且功能结局更有利。
  • 需进一步实验和临床研究证实该结果并阐明甲状腺激素替代治疗影响蛛网膜下腔出血病程与结局的机制背景。

研究设计与样本

  • 研究纳入2003年1月至2016年6月期间治疗的蛛网膜下腔出血患者,共995例,其中109例(11%)在出血前接受甲状腺激素替代治疗。
  • 记录患者与蛛网膜下腔出血的基线特征、不良事件及功能结局,研究终点为脑梗死、院内死亡和6个月时不良功能结局,关联分析对结局相关混杂因素进行了校正。

主要发现

  • 颅内压或血管痉挛相关脑血管事件风险与甲状腺激素替代治疗的存在呈负相关(p=0.047)。
  • 多因素分析中,甲状腺激素替代治疗与较低脑梗死风险独立相关(aOR=0.64,95%CI=0.41-0.99,p=0.045)。
  • 多因素分析中,甲状腺激素替代治疗与较低不良功能结局风险独立相关(aOR=0.50,95%CI=0.28-0.89,p=0.018)。
  • 多因素分析中,甲状腺激素替代治疗与院内死亡率无关(aOR=0.69,95%CI=0.38-1.26,p=0.227)。

局限性

  • 作者指出需进一步实验和临床研究证实该结果并阐明甲状腺激素替代治疗影响蛛网膜下腔出血病程与结局的机制背景。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Thyroid hormones were reported to exert neuroprotective effects after ischemic stroke by reducing the burden of brain injury and promoting post-ischemic brain remodeling. OBJECTIVE: We aimed to analyze the value of thyroid hormone replacement therapy (THRT) due to pre-existing hypothyroidism on the clinical course and outcome of aneurysmal subarachnoid hemorrhage (SAH). METHODS: SAH individuals treated between January 2003 and June 2016 were included. Data on baseline characteristics of patients and SAH, adverse events and functional outcome of SAH were recorded. Study endpoints were cerebral infarction, in-hospital mortality and unfavorable outcome at 6 months. Associations were adjusted for outcome-relevant confounders. RESULTS: 109 (11%) of 995 individuals had THRT before SAH. Risk of intracranial pressure- or vasospasm-related cerebrovascular events was inversely associated with presence of THRT (p = 0.047). In multivariate analysis, THRT was independently associated with lower risk of cerebral infarction (adjusted odds ratio [aOR] = 0.64, 95% confidence interval [CI] = 0.41-0.99, p = 0.045) and unfavorable outcome (aOR = 0.50, 95% CI = 0.28-0.89, p = 0.018), but not with in-hospital mortality (aOR = 0.69, 95% CI = 0.38-1.26, p = 0.227). CONCLUSION: SAH patients with THRT show lower burden of ischemia-relevant cerebrovascular events and more favorable outcome. Further experimental and clinical studies are required to confirm our results and elaborate the mechanistic background of the effect of THRT on course and outcome of SAH.

来源:Acta Neurochir (Wien),查看原文。版权归原作者所有。

引用

  1. Said M, Gümüs M, Rieß C, et al. Impact of thyroid hormone replacement therapy on the course and functional outcome of aneurysmal subarachnoid hemorrhage. Acta Neurochir (Wien). 2024. PMID: 38829543. doi:10.1007/s00701-024-06118-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。